Policy, Governance, Regulation & Global Cooperation
Supporting enabling policy, governance, ethical and regulatory environments.
Turning precisionmedicine intoequitable health impact
Advancing Equity.
Accelerating Implementation.
Why PMEA?
Innovation is accelerating, butimplementation is not
PMEA exists to close the implementation gap — without widening the equity gap.
Precision Medicine
The right approachFor the right personAt the right time
Better decisions about prevention, diagnosis and treatment.
The value of precision medicine
Better decisions
Shared value
Examples from specific studies. These findings relate to defined populations and settings and should not be interpreted as universal estimates.
21.5%vs28.6%
Clinically relevant adverse drug reactions with genotype-guided prescribing versus standard care.
Better information can support safer treatment choices.
Source: Swen et al., The Lancet, 2023.
31%vs3%
Critically ill infants diagnosed within 28 days with rapid whole-genome sequencing plus standard tests versus standard tests alone.
A faster answer can change care.
Source: Petrikin et al., npj Genomic Medicine, 2018.
About 70%
of women with HR-positive, HER2-negative, node-negative early breast cancer could avoid chemotherapy when care was guided by a 21-gene assay.
Precision can also mean doing less—safely.
Source: Sparano et al., NEJM, 2018; NCI.
More efficient
care
care
through better targeting and resource use.
Avoid ineffective interventions and support more sustainable value.
Earlier
action
action
through risk-informed prevention and detection.
Enable prevention, screening and timely intervention.
Study results and benefits vary by population, intervention and setting. Select “Know more” for context and limitations.
Our approach
Countries define the need
PMEA helps mobilise the ecosystem required to address it.
Four interconnected areas of action
Mobilising the ecosystem across the full implementation environment.
Country Readiness & Implementation Enablement
Turning national priorities into practical, locally owned implementation pathways.
Equity, Participation, Access & Sustainable Financing
Embedding lived experience, affordability and sustainable access from the outset.
Evidence & Implementation Learning
Generating practical intelligence, enabling capacity and advancing cross-country learning.
Partnerships connect all four areas. PMEA mobilises the expertise, institutions and implementation capacity required to respond to country-defined priorities.
How country engagement works
A six-stage pathway shaped by national priorities.
Governments retain ownership. PMEA helps connect evidence, expertise, participation and sustainability from request through follow-up.
01Government request
02Focused assessment
03Priority and roadmap
04Partners and sustainability
05Transition
06Follow-up and learning
About PMEA
Independent. Neutral. Multi-stakeholder
PMEA is being established as a non-profit organisation pursuing a public-interest mission. During its founding phase, it is led by its Co-Chairs and guided by an international Founding Advisory Council. Following formal establishment, a governing Board will assume strategic, fiduciary and organisational oversight.
Meet the Co-Chairs and Advisory Council
Co-Chairs
Founder & Co-Chair
Alexandra Heumber Perry
Founder & Co-Chair, Precision Medicine Equity Accelerator
Co-Chair
H.E. Prof. Dr. Khaled Abdel-Ghaffar
Minister of Health and Population of the Arab Republic of Egypt
Founding Advisory Council
Founding Advisory Council
Prof. Mohamed Hassany
Assistant Minister of Health for Projects and Public Health Initiatives
Founding Advisory Council
Dr Brian Chung
Interim Chief Executive Officer and Chief Medical and Scientific Officer, Hong Kong Genome Institute
Founding Advisory Council
Prof. Roberto Giugliani
Professor, Department of Genetics, UFRGS; Executive Director, Casa dos Raros; Head of Rare Diseases, Dasa Genomics
Founding Advisory Council
Sharon Terry
President and CEO, Genetic Alliance
Founding Advisory Council
Anne-Sophie Chalandon
Head of Global Public Affairs Vaccines, Pneumo, Meningo, Endemic and Travel Vaccines, Sanofi
Founding Advisory Council members participate in their individual capacity unless otherwise specified. Affiliations are provided for identification and do not imply institutional endorsement.
Partner with PMEA
From scientific possibility
to equitable health impact
Through country ownership, locally relevant pathways and coordinated multi-stakeholder action.